



(11) **EP 2 536 422 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 73**

(48) Corrigendum issued on:  
**21.06.2023 Bulletin 2023/25**

(45) Date of publication and mention  
of the grant of the patent:  
**30.04.2014 Bulletin 2014/18**

(21) Application number: **12703408.0**

(22) Date of filing: **01.02.2012**

(51) International Patent Classification (IPC):  
**A61K 38/08** <sup>(2006.01)</sup> **A61P 17/02** <sup>(2006.01)</sup>

(52) Cooperative Patent Classification (CPC):  
**A61K 38/085; A61P 3/10; A61P 17/00;**  
**A61P 17/02; A61P 43/00**

(86) International application number:  
**PCT/US2012/023484**

(87) International publication number:  
**WO 2012/106427 (09.08.2012 Gazette 2012/32)**

(54) **METHODS FOR TREATING DIABETIC FOOT ULCERS**

VERFAHREN ZUR BEHANDLUNG VON DIABETISCHEN FUSSGESCHWÜREN

PROCÉDÉS DE TRAITEMENT D'ULCÈRES DU PIED DIABÉTIQUE

(84) Designated Contracting States:  
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB**  
**GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO**  
**PL PT RO RS SE SI SK SM TR**

(30) Priority: **02.02.2011 US 201161438780 P**

(43) Date of publication of application:  
**26.12.2012 Bulletin 2012/52**

(73) Proprietor: **University of Southern California**  
**Los Angeles, CA 90089-2561 (US)**

(72) Inventors:  
• **RODGERS, Kathleen, E.**  
**Long Beach, CA 90815 (US)**  
• **DIZEREGA, Gere, S.**  
**San Luis Obispo, CA 93401 (US)**

(74) Representative: **Ettmayr, Andreas et al**  
**KEHL, ASCHERL, LIEBHOF & ETTMAYR**  
**Patentanwälte**  
**Emil-Riedel-Strasse 18**  
**80538 München (DE)**

(56) References cited:  
**WO-A1-2011/120032**

- **RODGERS K E ET AL: "Fragments of Nle3-angiotensin(1-7) accelerate healing in dermal models", JOURNAL OF PEPTIDE RESEARCH, BLACKWELL PUBLISHING LTD, OXFORD; GB, vol. 66, no. SUPPL. 1, 1 December 2005 (2005-12-01), pages 41-47, XP002643256, ISSN: 1397-002X**
- **RODGERS K E ET AL: "ACCELERATION OF HEALING, REDUCTION OF FIBROTIC SCAR, AND NORMALIZATION OF TISSUE ARCHITECTURE BY AN ANGIOTENSIN ANALOGUE, NORLEU3-A(1-7)", PLASTIC AND RECONSTRUCTIVE SURGERY, WILLIAMS AND WILKINS CO., BALTIMORE, MD, US, vol. 111, no. 3, 1 March 2003 (2003-03-01), pages 1195-1206, XP008059840, ISSN: 0032-1052, DOI: 10.1097/01.PRS.0000047403.23105.66**
- **KATHLEEN E. RODGERS ET AL: "Histological evaluation of the effects of angiotensin peptides on wound repair in diabetic mice", EXPERIMENTAL DERMATOLOGY, vol. 12, no. 6, 1 December 2003 (2003-12-01), pages 784-790, XP55032955, ISSN: 0906-6705, DOI: 10.1111/j.0906-6705.2003.00087.x**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 2 536 422 B8**

- **US-NIH: "Safety and Efficacy Study of DSC127 in Treating Subjects With Diabetic Ulcers"**, , 14 May 2010 (2010-05-14), XP002680220, Retrieved from the Internet:  
URL:<http://web.archive.org/web/20100514120507/http://www.clinicaltrials.gov/ct2/show/NCT00796744?> [retrieved on 2012-07-17]
- **MATUSZEWSKA BOZENA ET AL: "Acidic fibroblast growth factor: Evaluation of topical formulations in a diabetic mouse wound healing model"**, **PHARMACEUTICAL RESEARCH (NEW YORK)**, vol. 11, no. 1, 1994, pages 65-71, XP009161289, ISSN: 0724-8741
- **PETER P. BALINGIT ET AL: "NorLeu3-A(1-7) stimulation of diabetic foot ulcer healing: Results of a randomized, parallel-group, double-blind, placebo-controlled phase 2 clinical trial"**, **WOUND REPAIR AND REGENERATION**, 1 July 2012 (2012-07-01), pages N/A-N/A, XP55032963, ISSN: 1067-1927, DOI: 10.1111/j.1524-475X.2012.00804.x
- **CARNEY D H ET AL: "Could rusalatide acetate be the future drug of choice for diabetic foot ulcers and fracture repair?"**, **EXPERT OPINION ON PHARMACOTHERAPY 200810 GB LNKD-DOI:10.1517/14656566.9.15.2717**, vol. 9, no. 15, October 2008 (2008-10), pages 2717-2726, XP009161260, ISSN: 1465-6566

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification